Cardiolectus Limited Filleted Accounts Cover |
Company No. 09324973 | |||||||||
Cardiolectus Limited Directors Report Registrar |
The Directors present their report and the accounts for the year ended 31 October 2023. | |||||||||
Principal activities | |||||||||
Directors | |||||||||
The Directors who served at any time during the year were as follows: | |||||||||
C.G. Hanratty | |||||||||
J. Spratt | |||||||||
J.W. Strange | |||||||||
S.J. Walsh | |||||||||
Signed on behalf of the board | |||||||||
J.W. Strange | |||||||||
Director | |||||||||
09 September 2024 |
Cardiolectus Limited Balance Sheet Registrar |
at | ||||||||||
Company No. | Notes | 2023 | 2022 | |||||||
£ | £ | |||||||||
Fixed assets | ||||||||||
Investments | 3 | |||||||||
Current assets | ||||||||||
Debtors | 4 | |||||||||
Cash at bank and in hand | ||||||||||
Creditors: Amount falling due within one year | 5 | ( | ( | |||||||
Net current liabilities | ( | ( | ||||||||
Total assets less current liabilities | ||||||||||
Net assets | ||||||||||
Capital and reserves | ||||||||||
Called up share capital | ||||||||||
Share premium account | 7 | |||||||||
Profit and loss account | 7 | |||||||||
Total equity | ||||||||||
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account. | ||||||||||
Approved by the board on 09 September 2024 and signed on its behalf by: | ||||||||||
J.W. Strange | ||||||||||
Director | ||||||||||
09 September 2024 |
Cardiolectus Limited Notes to the Accounts Registrar |
for the year ended 31 October 2023 | ||||||||||||||
1 | General information | |||||||||||||
Cardiolectus Limited is a private company limited by shares and incorporated in England and Wales. | ||||||||||||||
Its registered number is: 09324973 | ||||||||||||||
Its registered office is: | ||||||||||||||
2 | Employees | |||||||||||||
2023 | 2022 | |||||||||||||
Number | Number | |||||||||||||
The average monthly number of employees (including directors) during the year was: | ||||||||||||||
3 | Investments | |||||||||||||
Other investments | Total | |||||||||||||
£ | £ | |||||||||||||
Cost or valuation | ||||||||||||||
At 1 November 2022 | ||||||||||||||
At 31 October 2023 | ||||||||||||||
Provisions/Impairment | ||||||||||||||
Net book values | ||||||||||||||
At 31 October 2023 | ||||||||||||||
At 31 October 2022 | ||||||||||||||
4 | Debtors | |||||||||||||
2023 | 2022 | |||||||||||||
£ | £ | |||||||||||||
Corporation tax recoverable | ||||||||||||||
5 | Creditors: | |||||||||||||
amounts falling due within one year | ||||||||||||||
2023 | 2022 | |||||||||||||
£ | £ | |||||||||||||
Other loans | ||||||||||||||
Loans from directors | ||||||||||||||
Accruals and deferred income | ||||||||||||||
6 | Share Capital | |||||||||||||
152 ordinary shares fully paid ay £1. | ||||||||||||||
7 | Reserves | |||||||||||||